SCHEMBL19994841

SCHEMBL19994841

Cc1cc(S(=O)(=O)NC2CCCCC2)ccc1Br

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.73
SMN1; SMN2 Q16637 3/20 0.67
GAA P10253 2/20 0.67
HTT P42858 2/20 0.63
CYP3A4 P08684 1/20 0.63
TSHR P16473 1/20 0.63
MAPK1 P28482 1/20 0.63
POLB P06746 1/20 0.63
KDM4E B2RXH2 2/20 0.60
RECQL P46063 1/20 0.60
TDP1 Q9NUW8 1/20 0.57
PDE4A P27815 1/20 0.56
PDE4B Q07343 1/20 0.56
PDE4C Q08493 1/20 0.56
PDE4D Q08499 1/20 0.56
HPGD P15428 2/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.54
PKM P14618 1/20 0.54
ALOX15 P16050 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2372122 0.92 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2GAAHTTCYP3A4
SCHEMBL21369122 0.88 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2GAAHTTCYP3A4
SCHEMBL1727236 0.86 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL19989503 0.86 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2GAAHTTCYP3A4
SCHEMBL29859380 0.86 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2GAAHTTCYP3A4
SCHEMBL29498481 0.86 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL848293 0.86 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL29498503 0.84 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2GAAHTTCYP3A4
SCHEMBL19989453 0.84 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2GAAHTTCYP3A4
SCHEMBL29859535 0.83 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2GAAHTTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515913-B1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2022-05-11 EP disclosed
CN-109715629-B Aza-indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-04-12 CN disclosed
US-11203595-B2 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG (CH) 2021-12-21 US disclosed
US-20210188842-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-06-24 US disclosed
US-10766894-B2 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG (CH) 2020-09-08 US disclosed
US-20190300522-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. 2019-10-03 US disclosed
EP-3515913-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
WO-2018055551-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766894-B2 Aza-indazole compounds for use in tendon and/or ligament injuries MMP1, TIMP3, ALPI ALDH1A1 348/4885SMN1; SMN2 1935/4885GAA 3883/4885
US-20190300522-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES MMP1, TIMP3, ALPI ALDH1A1 348/4885SMN1; SMN2 1935/4885GAA 3883/4885
US-20210188842-A1 AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES MMP1, ALPI, TIMP3 ALDH1A1 344/4885SMN1; SMN2 1763/4885GAA 3783/4885
US-11203595-B2 Aza-indazole compounds for use in tendon and/or ligament injuries MMP1, ALPI, TIMP3 ALDH1A1 344/4885SMN1; SMN2 1763/4885GAA 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.